The invention relates to a stable solid dosage form comprising olmesartan medoxomil and amlodipine or a pharmacologically acceptable salt thereof. In particular, it relates to solid dosage forms free from reducing sugars. The stable solid dosage form may optionally further comprise hydrochlorothiazide or a pharmacologically acceptable salt thereof.本發明係關於一種包含奧美沙坦酯(olmesartan medoxomil)及氨氯地平(amlodipine)或其藥理上可接受之鹽之安定固體劑型。特別,本發明係關於不含還原糖之固體劑型。該安定固體劑型視需要可進一步包含氫氯賽寨(hydrochlorothiazide)或其藥理上可接受鹽。
